This week in Clipboard Health’s Nursing News round up …
For the ninth straight week, COVID-19 numbers fell in the United States. Deaths declined 22%, dropping below 10,000 for the first time since the middle of November. New cases fell 10% to around 378,000 new cases. However, nineteen states reported more new infections last week compared to the week before; last week, there were only thirteen states that reported such numbers.
The US vaccination rates have now reached 2.4 million doses per day. In total, the US has administered over 109 million doses of COVID-19 vaccines.
Officials urge the public to continue following CDC guidelines to prevent infection, even as the number of people traveling via air reached the highest level it’s been since the pandemic began.
However, even as US numbers continue to decrease, the World Health Organization reported that it has seen an 11% increase in new COVID-19 cases worldwide.
After reports of serious side effects from the AstraZeneca vaccine, Germany, Italy, and France suspended the use of the vaccine indefinitely. Other countries, including Denmark, Norway, iceland, Bulgaria, Ireland, the Netherlands, and Spain, have also announced temporary or indefinite suspensions.
Meanwhile, the World Health Organization is currently reviewing the reports of the side effects, but the organization said it would be unlikely to change its recommendations to continue using the vaccine. Additionally, AstraZeneca reviewed its safety data and said that according to the data, receiving the AstraZeneca vaccine did not increase the risk of blood clots.
The controversy comes after a Danish woman died from a blood clot after she was given a dose of the AstraZeneca vaccine and three people in Norway reported “unusual symptoms.”
The United States may authorize the use of the AstraZeneca vaccine sometime in April according to a US official.
Eli Lilly and Co reported that results from its mid-stage drug trial for donanemab, its experimental drug to treat Alzheimer’s, slowed cognitive decline by about 32% in patients studied.
The antibody medication works by removing plaque found on the brain that is associated with Alzheimer’s disease. Patients most likely to benefit from the drug had lower levels of plaque.
The mid-stage trial involved 272 patients studied over the course of 18 months. The next trial will include 500 patients.
Here’s a brief round-up of recent medical studies and their findings for you to stay up-to-date with the ever-evolving field of medical research.
To learn more about the top COVID-19 vaccines, vaccination timelines, potential requirements for health care professionals and facilities, and more, check out our COVID-19 Vaccine Information hub.
Here’s some more of the most recent news from the past week concerning the COVID-19 pandemic.
Start booking shifts at healthcare facilities through Clipboard Health with competitive pay and no shift minimums in as little as 1-2 days!Sign Up Now
Combat talent shortages cost-effectively
Finding the right CNA, LVN/LPN, or RN to fill shifts because of unexpected vacancies, employee vacations, or hiring freezes can be challenging. Sign up for access to our online marketplace, and start finding fast, easy and cost-effective healthcare talent solutions.Find Talent